298 related articles for article (PubMed ID: 26182832)
1. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.
Jurcevic S; Humfrey C; Uddin M; Warrington S; Larsson B; Keen C
Br J Clin Pharmacol; 2015 Dec; 80(6):1324-36. PubMed ID: 26182832
[TBL] [Abstract][Full Text] [Related]
2. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
Kirsten AM; Förster K; Radeczky E; Linnhoff A; Balint B; Watz H; Wray H; Salkeld L; Cullberg M; Larsson B
Pulm Pharmacol Ther; 2015 Apr; 31():36-41. PubMed ID: 25681277
[TBL] [Abstract][Full Text] [Related]
3. The chemokine CXCR2 antagonist (AZD5069) preserves neutrophil-mediated host immunity in non-human primates.
Uddin M; Betts C; Robinson I; Malmgren A; Humfrey C
Haematologica; 2017 Feb; 102(2):e65-e68. PubMed ID: 27742769
[No Abstract] [Full Text] [Related]
4. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.
De Soyza A; Pavord I; Elborn JS; Smith D; Wray H; Puu M; Larsson B; Stockley R
Eur Respir J; 2015 Oct; 46(4):1021-32. PubMed ID: 26341987
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.
Nicholls DJ; Wiley K; Dainty I; MacIntosh F; Phillips C; Gaw A; Mårdh CK
J Pharmacol Exp Ther; 2015 May; 353(2):340-50. PubMed ID: 25736418
[TBL] [Abstract][Full Text] [Related]
6. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans.
Lazaar AL; Sweeney LE; MacDonald AJ; Alexis NE; Chen C; Tal-Singer R
Br J Clin Pharmacol; 2011 Aug; 72(2):282-93. PubMed ID: 21426372
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial.
O'Byrne PM; Metev H; Puu M; Richter K; Keen C; Uddin M; Larsson B; Cullberg M; Nair P
Lancet Respir Med; 2016 Oct; 4(10):797-806. PubMed ID: 27574788
[TBL] [Abstract][Full Text] [Related]
8. Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma.
Watz H; Uddin M; Pedersen F; Kirsten A; Goldmann T; Stellmacher F; Groth E; Larsson B; Böttcher G; Malmgren A; Kraan M; Rabe KF
Pulm Pharmacol Ther; 2017 Aug; 45():121-123. PubMed ID: 28549850
[No Abstract] [Full Text] [Related]
9. CXCR2 Inhibition - a novel approach to treating CoronAry heart DiseAse (CICADA): study protocol for a randomised controlled trial.
Joseph JP; Reyes E; Guzman J; O'Doherty J; McConkey H; Arri S; Kakkar R; Beckley N; Douiri A; Barrington SF; Redwood SR; Ferro A
Trials; 2017 Oct; 18(1):473. PubMed ID: 29020983
[TBL] [Abstract][Full Text] [Related]
10. The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects.
Todd CM; Salter BM; Murphy DM; Watson RM; Howie KJ; Milot J; Sadeh J; Boulet LP; O'Byrne PM; Gauvreau GM
Pulm Pharmacol Ther; 2016 Dec; 41():34-39. PubMed ID: 27640067
[TBL] [Abstract][Full Text] [Related]
11. Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist.
Seiberling M; Kamtchoua T; Stryszak P; Ma X; Langdon RB; Khalilieh S
Int Immunopharmacol; 2013 Oct; 17(2):178-83. PubMed ID: 23791619
[TBL] [Abstract][Full Text] [Related]
12. The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects.
Hastrup N; Khalilieh S; Dale DC; Hanson LG; Magnusson P; Tzontcheva A; Tseng J; Huyck S; Rosenberg E; Krogsgaard K
Cytokine; 2015 Apr; 72(2):197-203. PubMed ID: 25661195
[TBL] [Abstract][Full Text] [Related]
13. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
Rennard SI; Dale DC; Donohue JF; Kanniess F; Magnussen H; Sutherland ER; Watz H; Lu S; Stryszak P; Rosenberg E; Staudinger H
Am J Respir Crit Care Med; 2015 May; 191(9):1001-11. PubMed ID: 25695403
[TBL] [Abstract][Full Text] [Related]
14. Syntheses of a radiolabelled CXCR2 antagonist AZD5069 and its major human metabolite.
Hickey MJ; Allen PH; Caffrey M; Hansen P; Kingston LP; Wilkinson DJ
J Labelled Comp Radiopharm; 2016 Sep; 59(11):432-8. PubMed ID: 27461061
[TBL] [Abstract][Full Text] [Related]
15. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.
Holz O; Khalilieh S; Ludwig-Sengpiel A; Watz H; Stryszak P; Soni P; Tsai M; Sadeh J; Magnussen H
Eur Respir J; 2010 Mar; 35(3):564-70. PubMed ID: 19643947
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist.
Leaker BR; Barnes PJ; O'Connor B
Respir Res; 2013 Dec; 14(1):137. PubMed ID: 24341382
[TBL] [Abstract][Full Text] [Related]
17. Effects of exogenous recombinant human granulocyte colony-stimulating factor (filgrastim, rhG-CSF) on neutrophils of critically ill patients with systemic inflammatory response syndrome depend on endogenous G-CSF plasma concentrations on admission.
Weiss M; Voglic S; Harms-Schirra B; Lorenz I; Lasch B; Dumon K; Gross-Weege W; Schneider EM
Intensive Care Med; 2003 Jun; 29(6):904-914. PubMed ID: 12682721
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo effects of granulocyte colony-stimulating factor on neutrophils in glycogen storage disease type 1B: granulocyte colony-stimulating factor therapy corrects the neutropenia and the defects in respiratory burst activity and Ca2+ mobilization.
McCawley LJ; Korchak HM; Douglas SD; Campbell DE; Thornton PS; Stanley CA; Baker L; Kilpatrick L
Pediatr Res; 1994 Jan; 35(1):84-90. PubMed ID: 7510873
[TBL] [Abstract][Full Text] [Related]
19. The Effects of 16 Weeks of Exercise Training on Neutrophil Functions in Breast Cancer Survivors.
Bartlett DB; Hanson ED; Lee JT; Wagoner CW; Harrell EP; Sullivan SA; Bates LC; Alzer MS; Amatuli DJ; Deal AM; Jensen BC; MacDonald G; Deal MA; Muss HB; Nyrop KA; Battaglini CL
Front Immunol; 2021; 12():733101. PubMed ID: 34777343
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects.
Miller BE; Mistry S; Smart K; Connolly P; Carpenter DC; Cooray H; Bloomer JC; Tal-Singer R; Lazaar AL
BMC Pharmacol Toxicol; 2015 Jun; 16():18. PubMed ID: 26092545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
